Business, energy, technology, markets and global industry news from Business News Today

Respiratory Drug Delivery 2026

PharmaDeviceNews Respiratory Drug Delivery 2026
Representative image: A dry powder inhaler prototype is shown in a pharmaceutical research setting, reflecting Phillips Medisize’s focus on connected inhaler innovation, device-formulation alignment, and patient-centric respiratory drug delivery at RDD 2026.
Medical Devices & Diagnostics

Phillips Medisize targets formulation-device risk as inhaled therapies grow more complex

Inhalers are getting smarter, but complexity can backfire. Phillips Medisize is betting DPI success starts with patient-centric design.

Read More
Representative image: Aptar Pharma’s FDA-funded research into next-generation propellants highlights the scientific complexity behind greener metered-dose inhalers, where aerosol performance, device design and bioequivalence testing could shape the future of respiratory drug delivery.
Medical Devices & Diagnostics

Can Aptar Pharma help solve the bioequivalence challenge in next-generation inhalers?

Greener inhalers need more than lower-carbon chemistry. Aptar Pharma’s FDA-backed work tests the science regulators may need.

Read More